Sea Pharmaceuticals

Sea Pharmaceuticals is a neurotherapeutics company specializing in the development of new oral molecules for the treatment of tinnitus and epilepsy. The company invents, discovers, and advances research & development (R&D), and plans to commercialize Sea's own novel proprietary synthetic small molecules as innovative treatments for Tinnitus, Epilepsy, and other high medical need therapeutic neurology indications including genetic disorders of the CNS.

Sea Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $54.1M in funding across 32 round(s). With a team of 11-50 employees, Sea Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Sea Pharmaceuticals, raised $1.5M. Discover more about their projects, partnerships, and impact on our platform.